IL-1α是心肌梗死和慢性肾病中白细胞-内皮黏附的核心调节因子
研究探讨IL-1α在急性心肌梗死(AMI)和慢性肾病(CKD)炎症中的作用。发现AMI和CKD患者单核细胞表面IL-1α表达增高,与动脉粥样硬化心血管事件风险相关;小鼠中IL-1α(而非IL-1β)介导白细胞-内皮黏附,促进组织炎症损伤,阻断IL-1α可预防CKD进展。
要点
- AMI和CKD患者单核细胞表面IL-1α表达升高,与动脉粥样硬化心血管事件风险相关。
- 小鼠中IL-1α而非IL-1β介导白细胞-内皮黏附,促进巨噬细胞和中性粒细胞浸润。
- IL-1α通过IL-1受体-1介导单核细胞黏附,并上调内皮VCAM-1表达。
核心结论
- IL-1α是AMI和CKD中白细胞-内皮黏附和炎症的关键介质,抑制IL-1α可能成为新型抗炎治疗策略。
研究设计与样本
- 探索性临床研究评估AMI和CKD患者单核细胞表面IL-1α表达及其与动脉粥样硬化心血管事件的关系。
- 使用Il1a-/-和Il1b-/-小鼠在多种器官损伤模型中评估IL-1α的炎症效应,并在体外单核细胞和内皮细胞中研究机制。
主要发现
- AMI和CKD患者单核细胞表面IL-1α表达显著高于健康对照,且高表达与随访期动脉粥样硬化心血管事件风险增高相关。
- 小鼠活体显微镜显示IL-1α(而非IL-1β)介导白细胞-内皮黏附,并促进巨噬细胞和中性粒细胞在炎症组织积聚。
- 单核细胞表面IL-1α刺激其在血管损伤部位归巢;游离脂肪酸或草酸钙晶体等刺激诱导单核细胞IL-1α表面表达和释放,通过IL-1受体-1介导其与内皮黏附。
- IL-1α促进内皮细胞VCAM-1表达,促进循环白细胞黏附;实验性AMI后IL-1α诱导炎症损伤,阻断IL-1α可预防草酸或腺嘌呤喂养小鼠CKD发生。
临床怎么用
- IL-1α可作为AMI和CKD炎症评估的潜在生物标志物,但其临床阈值尚未确立。
- 抑制IL-1α可能为AMI和CKD患者提供新的抗炎治疗方向,但需进一步临床试验验证。
局限性
- 临床部分为探索性研究,样本量及事件数未在摘要中报告。
- 机制研究主要基于小鼠模型和体外实验,人体验证有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular diseases and chronic kidney disease (CKD) are highly prevalent, aggravate each other, and account for substantial mortality. Both conditions are characterized by activation of the innate immune system. The alarmin interleukin-1α (IL-1α) is expressed in a variety of cell types promoting (sterile) systemic inflammation. The aim of the present study was to examine the role of IL-1α in mediating inflammation in the setting of acute myocardial infarction (AMI) and CKD. METHODS: We assessed the expression of IL-1α on the surface of monocytes from patients with AMI and patients with CKD and determined its association with atherosclerotic cardiovascular disease events during follow-up in an explorative clinical study. Furthermore, we assessed the inflammatory effects of IL-1α in several organ injury models in Il1a-/- and Il1b-/- mice and investigated the underlying mechanisms in vitro in monocytes and endothelial cells. RESULTS: IL-1α is strongly expressed on the surface of monocytes from patients with AMI and CKD compared with healthy controls. Higher IL-1α surface expression on monocytes from patients with AMI and CKD was associated with a higher risk for atherosclerotic cardiovascular disease events, which underlines the clinical relevance of IL-1α. In mice, IL-1α, but not IL-1β, mediates leukocyte-endothelial adhesion as determined by intravital microscopy. IL-1α promotes accumulation of macrophages and neutrophils in inflamed tissue in vivo. Furthermore, IL-1α on monocytes stimulates their homing at sites of vascular injury. A variety of stimuli such as free fatty acids or oxalate crystals induce IL-1α surface expression and release by monocytes, which then mediates their adhesion to the endothelium via IL-1 receptor-1. IL-1α also promotes expression of the VCAM-1 (vascular cell adhesion molecule-1) on endothelial cells, thereby fostering the adhesion of circulating leukocytes. IL-1α induces inflammatory injury after experimental AMI, and abrogation of IL-1α prevents the development of CKD in oxalate or adenine-fed mice. CONCLUSIONS: IL-1α represents a key mediator of leukocyte-endothelial adhesion and inflammation in AMI and CKD. Inhibition of IL-1α may serve as a novel anti-inflammatory treatment strategy.
引用
- Schunk SJ, Triem S, Schmit D, et al. Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. Circulation. 2021. PMID: 34192892. doi:10.1161/CIRCULATIONAHA.121.053547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。